Drug Approval | July 24, 2024
Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The Issue opened on June 18, 2024 and closed on June 21, 2024
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
This strategic decision will unlock significant value for our scientific and industrial products business
Subscribe To Our Newsletter & Stay Updated
